» Articles » PMID: 24511225

Periorbital Muscle Atrophy Associated with Topical Bimatoprost Therapy

Overview
Journal Clin Ophthalmol
Publisher Dove Medical Press
Specialty Ophthalmology
Date 2014 Feb 11
PMID 24511225
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Topical Bimatoprost is a common and popular prostaglandin analog used as an ocular hypotensive agent in the treatment of glaucoma. Side effects include ocular hyperaemia, ocular pruritus, and periocular and iris pigmentary changes. Perioribital lipodystrophy is another well-documented outcome associated with chronic use of topical bimatoprost, which results in periorbital hallowing, upper eyelid sulcus deepening, eyelid retraction and enophthalmos. We report an unusual case of periocular muscle atrophy and weakness from unilateral topical bimatoprost use. Our patient had primary angle closure and experienced a right upper eyelid ptosis 2 months after she started to use topical bimatoprost in that eye. Clinical measurements of her eyelids clearly showed reduction in the function of her right levator muscle, suggesting that effects of topical bimatoprost may not be limited to periorbital fat. She was advised to stop topical bimatoprost and right ptosis correction surgery with levator muscle advancement was performed successfully. Ophthalmologists and patients should be aware of this potential rare side effect of topical bimatoprost, as it may be potentially disfiguring, especially with monocular use. However, its exact mechanism of action needs to be clarified further.

Citing Articles

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.

Wu S, Huang C, Wang Y, Li X, Zhang S, Chen X Ther Adv Drug Saf. 2024; 15:20420986241285929.

PMID: 39429679 PMC: 11487502. DOI: 10.1177/20420986241285929.


Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.

Contreras-Salinas H, Romero-Lopez M, Olvera-Montano O, Rodriguez-Herrera L BMJ Open Ophthalmol. 2024; 9(1).

PMID: 39209740 PMC: 11367404. DOI: 10.1136/bmjophth-2024-001764.


From Eye Care to Hair Growth: Bimatoprost.

Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794131 PMC: 11124470. DOI: 10.3390/ph17050561.


New role for the anandamide metabolite prostaglandin F ethanolamide: Rolling preadipocyte proliferation.

Boubertakh B, Courtemanche O, Marsolais D, Di Marzo V, Silvestri C J Lipid Res. 2023; 64(11):100444.

PMID: 37730163 PMC: 10622703. DOI: 10.1016/j.jlr.2023.100444.


Bimatoprost in Dermatology.

Jha A, Sarkar R, Udayan U, Roy P, Jha A, Chaudhary R Indian Dermatol Online J. 2018; 9(3):224-228.

PMID: 29854658 PMC: 5956885. DOI: 10.4103/idoj.IDOJ_62_16.


References
1.
Miller C, Casimir D, Ntambi J . The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996; 137(12):5641-50. DOI: 10.1210/endo.137.12.8940395. View

2.
Jayaprakasam A, Ghazi-Nouri S . Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29(6):357-9. DOI: 10.3109/01676830.2010.527028. View

3.
Whitcup S, Cantor L, VanDenburgh A, Chen K . A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol. 2002; 87(1):57-62. PMC: 1771463. DOI: 10.1136/bjo.87.1.57. View

4.
Filippopoulos T, Paula J, Torun N, Hatton M, Pasquale L, Grosskreutz C . Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008; 24(4):302-7. DOI: 10.1097/IOP.0b013e31817d81df. View

5.
Doshi M, Edward D, Osmanovic S . Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology. 2006; 113(11):1961-7. DOI: 10.1016/j.ophtha.2006.05.041. View